Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000097

Senior Vice President, Finance sold 10,019 shares at an average $92.43 ($926,010)

  • Senior Vice President, Finance acquired 9,459 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Agarwal Arjun · Senior Vice President, Finance

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-09-11 Exercise or conversion : show line 1 in the form 10b5-1 +8,000 $12.50 $100,000 23,312 D
2026-09-11 Exercise or conversion : show line 2 in the form 10b5-1 +1,459 $34.39 $50,175 24,771 D
2026-09-11 Sale : show line 3 in the form 10b5-1 −3,000 $91.11 $273,322 21,771 D
2026-09-11 Sale : show line 4 in the form 10b5-1 −4,051 $92.41 $374,367 17,720 D
2026-09-11 Sale : show line 5 in the form 10b5-1 −2,208 $93.26 $205,921 15,512 D
2026-09-11 Sale : show line 6 in the form 10b5-1 −200 $94.02 $18,803 15,312 D
2026-09-15 Sale : show line 7 in the form 10b5-1 −560 $95.71 $53,598 14,752 D
Open-market sales · 10,019 sh · avg $92.43 · $926,010

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-09-11 Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) −8,000 84,917 D
2026-09-11 Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (right to buy) −1,459 58,333 D
Loading xslF345X06/form4.xml…